{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T06:38:05Z","timestamp":1789713485081,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,3,11]],"date-time":"2008-03-11T00:00:00Z","timestamp":1205193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1007\/s10549-008-9949-9","type":"journal-article","created":{"date-parts":[[2008,3,10]],"date-time":"2008-03-10T14:43:20Z","timestamp":1205160200000},"page":"491-499","source":"Crossref","is-referenced-by-count":22,"title":["Estrogen suppression in premenopausal women following 8\u00a0weeks of treatment with exemestane and triptorelin versus triptorelin alone"],"prefix":"10.1007","volume":"113","author":[{"given":"Maria Gabriella","family":"Jannuzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Di Salle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Pirotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akintunde","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,3,11]]},"reference":[{"key":"9949_CR1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","volume":"19","author":"JG Klijn","year":"2001","unstructured":"Klijn JG, Blamey RW, Boccardo F et al (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343\u2013353","journal-title":"J Clin Oncol"},{"key":"9949_CR2","first-page":"1101","volume":"3","author":"DC Johannessen","year":"1997","unstructured":"Johannessen DC, Engan T, Di Salle E et al (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3:1101\u20131108","journal-title":"Clin Cancer Res"},{"key":"9949_CR3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2002.20.3.751","volume":"20","author":"J Geisler","year":"2002","unstructured":"Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751\u2013757","journal-title":"J Clin Oncol"},{"key":"9949_CR4","first-page":"2089","volume":"4","author":"J Geisler","year":"1998","unstructured":"Geisler J, King N, Anker G et al (1998) In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4:2089\u20132093","journal-title":"Clin Cancer Res"},{"key":"9949_CR5","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/er.2004-0015","volume":"26","author":"RW Brueggemeier","year":"2005","unstructured":"Brueggemeier RW, Hackett JC, Diaz-Cruz ES (2005) Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331\u2013345","journal-title":"Endocr Rev"},{"key":"9949_CR6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1521-690X(03)00044-7","volume":"18","author":"WR Miller","year":"2004","unstructured":"Miller WR (2004) Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 18:1\u201332","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"9949_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)00305-1","volume":"30","author":"P Lonning","year":"2003","unstructured":"Lonning P, Pfister C, Martoni A, Zamagni C (2003) Pharmacokinetics of third-generation aromatase inhibitors. Semin Oncol 30:23\u201332","journal-title":"Semin Oncol"},{"key":"9949_CR8","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","volume":"18","author":"M Kaufmann","year":"2000","unstructured":"Kaufmann M, Bajetta E, Dirix LY et al (2000) Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 18:1399\u20131411","journal-title":"J Clin Oncol"},{"key":"9949_CR9","unstructured":"AROMASIN\u00ae (exemestane) (2005) Full prescribing information. Pharmacia & Upjohn Co, Division of Pfizer Inc., New York, NY"},{"key":"9949_CR10","first-page":"130","volume":"77","author":"M Filicori","year":"1993","unstructured":"Filicori M, Flamigni C, Cognigni G et al (1993) Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 77:130\u2013133","journal-title":"J Clin Endocrinol Metab"},{"key":"9949_CR11","volume-title":"Pharmaceutical statistics: practical and clinical applications","author":"S Bolton","year":"1990","unstructured":"Bolton S (1990) Pharmaceutical statistics: practical and clinical applications, 2nd edn. Marcel Dekker Inc., New York, NY","edition":"2"},{"key":"9949_CR12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1634\/theoncologist.6-6-538","volume":"6","author":"LB Michaud","year":"2001","unstructured":"Michaud LB, Jones KL, Buzdar AU (2001) Combination endocrine therapy in the management of breast cancer. Oncologist 6:538\u2013546","journal-title":"Oncologist"},{"key":"9949_CR13","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1586\/14737140.5.4.591","volume":"5","author":"A Rody","year":"2005","unstructured":"Rody A, Loibl S, von Minckwitz G, Kaufmann M (2005) Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 5:591\u2013604","journal-title":"Expert Rev Anticancer Ther"},{"key":"9949_CR14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.breast.2005.08.019","volume":"14","author":"M Dowsett","year":"2005","unstructured":"Dowsett M, Folkerd E, Doody D, Haynes B (2005) The biology of steroid hormones and endocrine treatment of breast cancer. Breast 14:452\u2013457","journal-title":"Breast"},{"key":"9949_CR15","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","volume":"24","author":"IE Smith","year":"2006","unstructured":"Smith IE, Dowsett M, Yap YS et al (2006) Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 24:2444\u20132447","journal-title":"J Clin Oncol"},{"key":"9949_CR16","unstructured":"National Comprehensive Cancer Network (2007) Clinical practice guidelines in oncology: breast cancer, Version 2, 2007. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/breast.pdf . Cited July 26, 2007"},{"key":"9949_CR17","first-page":"2261","volume":"19","author":"L Celio","year":"1999","unstructured":"Celio L, Martinetti A, Ferrari L et al (1999) Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 19:2261\u20132268","journal-title":"Anticancer Res"},{"key":"9949_CR18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1023\/A:1006289811540","volume":"56","author":"M Dowsett","year":"1999","unstructured":"Dowsett M, Doody D, Miall S et al (1999) Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer. Breast Cancer Res Treat 56:25\u201334","journal-title":"Breast Cancer Res Treat"},{"key":"9949_CR19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.bjc.6601557","volume":"90","author":"DP Forward","year":"2004","unstructured":"Forward DP, Cheung KL, Jackson L, Robertson JF (2004) Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer 90:590\u2013594","journal-title":"Br J Cancer"},{"key":"9949_CR20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.2165\/00003495-200059060-00007","volume":"59","author":"D Clemett","year":"2000","unstructured":"Clemett D, Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279\u20131296","journal-title":"Drugs"},{"key":"9949_CR21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF03033716","volume":"8","author":"M Dank","year":"2002","unstructured":"Dank M (2002) The role of aromasin in the hormonal therapy of breast cancer. Pathol Oncol Res 8:87\u201392","journal-title":"Pathol Oncol Res"},{"key":"9949_CR22","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","volume":"350","author":"RC Coombes","year":"2004","unstructured":"Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081\u20131092","journal-title":"N Engl J Med"},{"key":"9949_CR23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","volume":"14","author":"R Paridaens","year":"2003","unstructured":"Paridaens R, Dirix L, Lohrisch C et al (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391\u20131398","journal-title":"Ann Oncol"},{"key":"9949_CR24","unstructured":"Trelstar\u00ae Depot (triptorelin pamoate for injectable suspension) (2006) Full prescribing information. Watson Pharma, Inc., Corona, CA"},{"key":"9949_CR25","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1200\/JCO.2005.11.050","volume":"23","author":"S Dellapasqua","year":"2005","unstructured":"Dellapasqua S, Colleoni M, Gelber RD, Goldhirsch A (2005) Adjuvant endocrine therapy for premenopausal women with early breast cancer. J Clin Oncol 23:1736\u20131750","journal-title":"J Clin Oncol"},{"key":"9949_CR26","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.2005.09.121","volume":"23","author":"EP Winer","year":"2005","unstructured":"Winer EP, Hudis C, Burstein HJ et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 23:619\u2013629","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-9949-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-008-9949-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-008-9949-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T16:32:13Z","timestamp":1559233933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-008-9949-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,11]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["9949"],"URL":"https:\/\/doi.org\/10.1007\/s10549-008-9949-9","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,11]]}}}